Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC).
Stephen Michael Keefe
Research Funding - Cerulean Pharma
Daniel Heitjan
No relevant relationships to disclose
Meliessa Hennessey
Employment or Leadership Position - Cerulean Pharma
Janelle Robinson
Research Funding - Cerulean Pharma
Kristine Mykulowicz
Research Funding - Cerulean Pharma
Amy Marshall
Research Funding - Cerulean Pharma
Orvar Gunnarsson
No relevant relationships to disclose
Ronac Mamtani
No relevant relationships to disclose
David J. Vaughn
No relevant relationships to disclose
Jean H. Hoffman-Censits
No relevant relationships to disclose
Katherine L. Nathanson
No relevant relationships to disclose
Priti Lal
No relevant relationships to disclose
Daniel A. Pryma
No relevant relationships to disclose
Scott Eliasof
Employment or Leadership Position - Cerulean Pharma
Edward Graeme Garmey
Employment or Leadership Position - Cerulean Pharma
Roger B. Cohen
Consultant or Advisory Role - Cerulean Pharma
Naomi B. Haas
Research Funding - Cerulean Pharma